Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.

Jason Haukoos, MD, MSc, FACEP, shares the decade-long journey behind the DETECT Hep C trial and why emergency departments are key to implementing CDC screening guidelines.

The designation is for the company’s, TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.

Carly Ching, PhD’s analysis reveals that global AMR policies overemphasize human health while neglecting farmer-focused messaging that could improve adoption and impact.

In our latest podcast, first author Elizabeth Marlowe, PhD, D(ABMM), offers insights on her study looking at this ongoing issue, including the need for increased testing and getting patients into the continuum of care in a more efficient manner.

At IAS 2025, Luisa Stamm, MD, PhD, explains the NRTTI’s mechanism, study setup, and key data on HIV prevention efforts.

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae.

At IAS 2025, the VOLITION and OPERA study data presented at IAS 2025 show patient preference and real-world use of injectable CAB + RPV LA, informing the treatment strategy of ViiV CMO Jean van Wyk.

Yale School of Medicine’s Department of Pathology has embraced the booming field of digital pathology, where digital scanners and AI are improving speed and accuracy.

Study findings underscore the cost-effectiveness of more frequent hepatitis C testing among people who inject drugs, compared to less frequent or no testing at all.

Shortening the OraQuick HCV antibody test from 20 to 5 minutes reduced false positives and unnecessary follow-up RNA testing, but detected fewer viremic individuals.

This week, a mother's struggle with C difficile during pregnancy, racial disparities in COVID-19 treatment, Supreme Court decision preserving access to HIV prevention, and more.

The company said it expects to have its updated mRNA-1273 (Spikevax) vaccine available for these eligible populations in the US for the next respiratory virus season.

Quality improvement initiative at Henry Ford Health demonstrates streamlined workflow, rapid prior authorization, and low patient copayments; highlights opportunities for enhanced pharmacist involvement and education.

DETECT Hep C trial shows nontargeted testing in emergency departments outperforms risk-based screening, yet treatment follow-through remains low.

Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.

Gilead Sciences has partnered with the Global Fund to supply up to 2 million doses of its long-acting HIV prevention drug, lenacapavir, to low and lower-middle income countries.

This investigational two-drug regimen for treatment of adults with virologically suppressed HIV was given a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Sara Embry discusses her experience with the infection while pregnant and as a mother to young children as well as finding the Peggy Lillis Foundation to help her cope with the infection and subsequently work as a peer support volunteer for the organization.

Carl Schmid on the US Supreme Court ruling, proposed Centers for Disease Control and Prevention cuts, stigma, and why equitable PrEP access, including new long-acting options, depends on more than insurance.

A wearable health monitor synced with a smartphone app could enable remote detection of early SARS-CoV-2 infection.

Rebecca Bromley-Dulfano, MS, says expanding access to home testing and virtual care is key to closing racial gaps in treatment.

HIV+Hepatitis Policy Institute director discusses PrEP access, insurer compliance, and challenges ahead following the landmark decision.

Invivyd forms the SPEAR Study Group to evaluate pemivibart for Long COVID and post-vaccine syndrome, exploring monoclonal antibody treatment of spike protein.

Six health organizations and a physician challenge the legality of rescinded vaccine recommendations and dismissal of federal advisory members.